#USA #Oxford Biomarkers #Mira Precision Health #ToxNav #Mason, Ohio

Advancing Cancer Treatment in the USA

In a landmark collaboration, Oxford Cancer Biomarkers Ltd (OCB) has partnered with Mira Precision Health Inc to advance the implementation of its ToxNav® test in the United States. Announced following the prestigious 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, this partnership aims to improve cancer treatment safety for patients undergoing 5FU/capecitabine therapy, which can often lead to severe toxicity and even death for some patients.

A Revolutionary Test for Precision Oncology

ToxNav® is a groundbreaking precision oncology test that provides crucial information on patient susceptibility to harsh side effects from widely used cancer drugs like 5FU and capecitabine. With the collaboration, Oxford Cancer Biomarkers seeks to enhance its presence in a growing market while ensuring that healthcare providers and clinics can offer better patient outcomes through effective toxicity screening.

Dr. David Kerr, the founder and director of OCB, who also holds a professorship in Cancer Medicine at Oxford University, highlighted the importance of ToxNav® in clinical settings. He stated, "Our goal with ToxNav is to identify patients at high risk of experiencing extreme toxicity from treatments that are commonly prescribed. This partnership with Mira Precision Health extends the clinical applicability of our test in the U.S., ultimately aiming to save lives."

Mira Precision Health's Role

Mira Precision Health, headquartered in Mason, Ohio, is committed to transforming healthcare through innovation and the delivery of advanced molecular diagnostic solutions directly to healthcare providers. Dr. Sandra Gunselman, the founder and CEO of Mira, expressed her excitement about this partnership, noting the potential to influence precision medicine in clinical practice.

Gunselman said, "Joining forces with Oxford Cancer Biomarkers allows us to integrate cutting-edge diagnostic solutions into everyday healthcare scenarios. The commitment from both teams to enhance patient care through precision medicine is a vital step towards improved outcomes."

Importance of DPYD Testing

The ToxNav® test aligns with recent updates from the National Comprehensive Cancer Network (NCCN), which recommended routine DPYD testing for colorectal cancer patients receiving fluoropyrimidine-based therapies. This correlation emphasizes the timely relevance of the ToxNav® test in helping clinicians make informed treatment decisions, thereby reducing incidences of unnecessary toxicity.

Karen Merritt, a co-founder of Advocates for Universal DPD/DPYD Testing, praised the collaboration, calling it a significant advancement toward comprehensive pre-treatment screening, ensuring patient safety and potentially saving lives.

Looking Ahead

The partnership aims to reinforce the commitment to advancing personalized cancer care while alleviating healthcare costs associated with severe adverse drug reactions. Shaun Peterson, Vice President of Sales and Marketing at Mira Precision Health, pointed out how multiple peer-reviewed studies support the effectiveness of the ToxNav® test. The collaboration is expected to expand reach within the U.S. healthcare system, improving patient outcomes through better clinical decision-making.

As both organizations forge ahead, the City of Mason is optimistic about the impact of this partnership on local biohealth initiatives. Michele Blair, Director of Economic Development for the City, remarked on the growing synergy between technological advancements in healthcare and the dynamics of the local economy.

Oxford Cancer Biomarkers: A Brief Overview

Founded as a spin-out from the University of Oxford, OCB specializes in developing state-of-the-art molecular and AI-driven diagnostic equipment aimed at optimizing cancer treatment strategies. Their commitment to expanding their portfolio includes an array of novel biomarkers and proprietary algorithms that support personalized treatment planning.

Conclusion

The partnership between Oxford Cancer Biomarkers and Mira Precision Health marks a significant step forward in cancer treatment, making strides toward increased patient safety during chemotherapy sessions. As they work together to implement the ToxNav® test in the United States, both organizations are setting the stage for groundbreaking advancements in precision medicine that have the potential to save lives. Through collaborations that emphasize innovation and patient-centric care, the healthcare landscape continues to evolve, demonstrating the impactful intersection of research, technology, and compassionate medical practices.